Research launched to tackle fibrosis
Inosi Therapeutics (Inosi), a company based on Monash University research, has launched with an investment from IP Group and BioCurate. Formed to enhance the partnership of academia and industry partners, Inosi aims to align new therapy development programs with unmet patient and market needs around fibrosis.
Inosi’s technology is based on collaborative research from members of Monash Biomedicine Discovery Institute and MIPS’ Associate Professor Philip Thompson, with Monash Innovation leading the deal.
Fibrosis is closely associated with tissue injury and scarring that occurs with chronic diseases and is responsible for a large proportion of healthcare costs and mortality in developed countries.